Skip to main content
RYTM
NASDAQ Life Sciences

Rhythm Pharma Q1 Revenue Jumps 84% to $60.1M on IMCIVREE Success

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$92
Mkt Cap
$5.844B
52W Low
$55.31
52W High
$122.2
52W Position info
66% above low
Off High info
25% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

RYTM sits 66% above its 52-week low of $55.31.

Summary

Rhythm Pharmaceuticals reported a robust 84% year-over-year increase in Q1 product revenue, reaching $60.11 million, primarily driven by the successful launch and continued uptake of its drug IMCIVREE for acquired hypothalamic obesity and Bardet-Biedl syndrome. This strong revenue growth builds on the positive momentum from the recent marketing authorization for IMCIVREE. While the company's Q1 net loss of $55.64 million was slightly wider than analyst expectations, the significant top-line expansion underscores the commercial success of its key product. Management also provided 2026 non-GAAP operating expense guidance of $385 million to $415 million and anticipates a Japan PMDA decision on IMCIVREE in acquired hypothalamic obesity in the second half of 2026, with European launches expected in 2027. This report indicates strong product execution and provides a clear growth trajectory for the company.

At the time of this announcement, RYTM was trading at $92.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $55.31 to $122.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

RYTM - Latest Insights

RYTM
Nov 16, 2026, 4:00 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $107.31
Real-time Price: $114.66 info
Change: +$7.35 (+7%) info
Market Cap: $7.996B info
RYTM
Nov 06, 2026, 11:06 AM EST
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $109.39
Real-time Price: $114.66 info
Change: +$5.27 (+5%) info
Market Cap: $7.996B info
RYTM
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $109.75
Real-time Price: $114.66 info
Change: +$4.91 (+4%) info
Market Cap: $7.996B info
RYTM
Nov 04, 2026, 3:57 PM EST
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $95.21
Real-time Price: $114.66 info
Change: +$19.45 (+20%) info
Market Cap: $7.996B info
RYTM
Nov 04, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $85.70
Real-time Price: $114.66 info
Change: +$28.96 (+34%) info
Market Cap: $7.996B info